Higher-risk APS: do we dare to DOAC?

Abstract

In this issue of Blood, Pengo et al present a randomized control trial comparing the use of rivaroxaban and warfarin in high-risk patients with antiphospholipid antibody syndrome (APS). The trial was stopped early because of an increased number of events in the rivaroxaban arm.1

Authors

Laureano M; Crowther MA

Journal

Blood, Vol. 132, No. 13, pp. 1357–1358

Publisher

American Society of Hematology

Publication Date

September 27, 2018

DOI

10.1182/blood-2018-08-867036

ISSN

0006-4971

Associated Experts

Mark Crowther

Professor, FHSMED

Visit profile

Labels